See the DrugPatentWatch profile for yervoy

According to the FDA label for Yervoy (ipilimumab), an immune checkpoint inhibitor used in cancer treatment, higher doses may lead to increased frequency and severity of adverse reactions. These side effects can include immune-mediated adverse reactions affecting various organs, skin reactions, gastrointestinal issues, and hepatic toxicity. The risk of severe and fatal immune-mediated adverse reactions also increases with higher doses. It is crucial for healthcare providers to monitor patients closely for any signs of adverse reactions and to manage them promptly. Research published on PubMed supports these findings, emphasizing the importance of vigilance and early intervention when using Yervoy at higher doses to minimize the risk of serious side effects [3][2][1].

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] https://pubmed.ncbi.nlm.nih.gov/29975414/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf